Linden Thomas Advisory Services LLC Has $2.03 Million Stock Position in Cencora, Inc. (NYSE:COR)

Linden Thomas Advisory Services LLC boosted its stake in shares of Cencora, Inc. (NYSE:COR) by 15.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,012 shares of the company’s stock after acquiring an additional 1,239 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Cencora were worth $2,025,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Concord Wealth Partners acquired a new stake in shares of Cencora in the third quarter valued at approximately $30,000. Householder Group Estate & Retirement Specialist LLC increased its stake in shares of Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after buying an additional 69 shares during the period. Ashton Thomas Securities LLC acquired a new stake in shares of Cencora in the 3rd quarter valued at $41,000. Modus Advisors LLC bought a new stake in shares of Cencora during the fourth quarter worth $54,000. Finally, Carolina Wealth Advisors LLC lifted its stake in shares of Cencora by 366.7% during the third quarter. Carolina Wealth Advisors LLC now owns 266 shares of the company’s stock valued at $60,000 after acquiring an additional 209 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Performance

NYSE:COR opened at $248.45 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84. The stock has a market cap of $48.02 billion, a P/E ratio of 33.08, a PEG ratio of 1.54 and a beta of 0.49. The stock has a 50 day simple moving average of $237.51 and a 200 day simple moving average of $234.66. Cencora, Inc. has a 1-year low of $214.77 and a 1-year high of $253.27.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date of this dividend was Friday, November 15th. This is a positive change from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio is presently 29.29%.

Analyst Upgrades and Downgrades

A number of analysts recently commented on COR shares. Mizuho initiated coverage on Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective for the company. Barclays lifted their target price on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. upped their price target on shares of Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday. Evercore ISI boosted their target price on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Finally, Leerink Partners decreased their target price on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and an average price target of $277.00.

Insider Transactions at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the completion of the sale, the chairman now directly owns 306,752 shares in the company, valued at $74,283,064.32. This represents a 6.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the firm’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the sale, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 73,187 shares of company stock valued at $17,790,912. 15.80% of the stock is currently owned by company insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.